Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program.

MLA

le Roux, Carel W., et al. “Tirzepatide for the Treatment of Obesity: Rationale and Design of the SURMOUNT Clinical Development Program.” Obesity (19307381), vol. 31, no. 1, Jan. 2023, pp. 96–110. EBSCOhost, https://doi.org/10.1002/oby.23612.

APA

le Roux, C. W., Zhang, S., Aronne, L. J., Kushner, R. F., Chao, A. M., Machineni, S., Dunn, J., Chigutsa, F. B., Ahmad, N. N., & Bunck, M. C. (2023). Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program. Obesity (19307381), 31(1), 96–110. https://doi.org/10.1002/oby.23612

Chicago

le Roux, Carel W., Shuyu Zhang, Louis J. Aronne, Robert F. Kushner, Ariana M. Chao, Sriram Machineni, Julia Dunn, Farai B. Chigutsa, Nadia N. Ahmad, and Mathijs C. Bunck. 2023. “Tirzepatide for the Treatment of Obesity: Rationale and Design of the SURMOUNT Clinical Development Program.” Obesity (19307381) 31 (1): 96–110. doi:10.1002/oby.23612.